The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to evaluate the effectiveness, safety, and tolerability of itepekimab in adults who have chronic rhinosinusitis with nasal polyps that are not well controlled. Participants in the study will receive either itepekimab or a placebo through an injection once a week for a total of 52 weeks, which is about one year. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if itepekimab can help reduce the symptoms of nasal polyps and improve the quality of life for those affected by this condition.

By participating in this study, researchers hope to gather important information about how itepekimab can help people with chronic rhinosinusitis with nasal polyps. This could lead to better treatment options in the future for those suffering from this condition. The study will also monitor any side effects or adverse reactions to ensure the safety of the participants. The results of this study could provide valuable insights into managing and treating chronic rhinosinusitis with nasal polyps more effectively.

The purpose of the study is to determine which of these two drugs provides a better improvement in symptoms related to the nasal polyp disease. Over a period of 12 months, participants will receive one of the medications to see how it affects their breathing, their sense of smell, and their overall quality of life. The study will monitor various changes in symptoms and physical health to evaluate how well each treatment works in a real-world setting.

The purpose of the study is to identify specific markers in the body, known as biomarkers, that can predict how well a patient with CRSwNP will respond to treatment with Mepolizumab. The study will also explore how cells from patients react to Mepolizumab in a laboratory setting, which may help understand the immune responses involved in these conditions. Participants in the study will receive either Mepolizumab or a placebo, and their responses will be monitored over a period of six months.

Throughout the study, researchers will collect information on how the treatment affects symptoms and the immune system. This includes looking at changes in nasal symptoms and examining how cells and molecules in the body respond to the treatment. The study aims to provide insights that could lead to better treatment strategies for people with CRSwNP and CRSsNP in the future.

The purpose of this study is to evaluate the long-term safety and tolerability of lunsekimig in participants who have previously completed a related study. Participants will receive lunsekimig injections and continue using their regular nasal spray medication. The study will monitor participants over a period of time to observe any side effects and to assess how well the treatment works in managing their symptoms.

Throughout the study, various assessments will be conducted, including changes in symptom scores and smell tests, as well as measuring the levels of lunsekimig in the blood. The study aims to provide valuable information on the long-term use of lunsekimig for managing CRSwNP, helping to determine its safety and effectiveness for patients with this condition.

The purpose of this study is to evaluate the effects of reducing the frequency of these medications in patients who have shown stable, partly controlled symptoms. Participants in the study will have been receiving either Dupilumab or Mepolizumab for at least 18 months, with their symptoms being partly controlled for at least 12 months. The study will last for 52 weeks, during which the dosing intervals of the medications will be gradually extended. The main goal is to determine how many patients can maintain partly controlled symptoms with less frequent dosing.

Throughout the study, participants will be monitored to assess changes in their symptoms and overall disease control. This will involve regular check-ups to evaluate nasal blockage, runny nose, facial pain, sense of smell, and the need for additional treatments. The study aims to provide insights into whether patients with CRSwNP can maintain symptom control with less frequent medication, potentially leading to more convenient treatment options in the future.

The purpose of the study is to evaluate how effective itepekimab is in reducing the size of nasal polyps and relieving nasal congestion compared to a placebo. Participants in the study will receive either itepekimab or a placebo through a subcutaneous injection, which means the medication is injected under the skin. The study will last for 52 weeks, during which participants will be monitored for changes in their symptoms and any side effects they might experience.

Throughout the study, participants will undergo various assessments to track their progress. These assessments will include checking the size of the nasal polyps and the level of nasal congestion. The study will also look at other symptoms like loss of smell and sinus opacification, which refers to the cloudiness seen in the sinuses on a computed tomography (CT) scan. The trial aims to provide valuable information on the safety and effectiveness of itepekimab for people with chronic rhinosinusitis with nasal polyps.

The purpose of the study is to observe changes in symptoms experienced by participants after starting treatment with Tezepelumab. Participants will report on their nasal congestion and other sinus-related symptoms over the course of the study. The study will last for 24 weeks, during which participants will receive regular injections of Tezepelumab and will be asked to keep a diary of their symptoms.

Throughout the study, changes in nasal congestion and other symptoms will be measured to assess the effectiveness of Tezepelumab. Participants will be monitored for any improvements in their condition, such as reduced nasal congestion and better sleep quality. The study aims to provide valuable information on how Tezepelumab can help manage symptoms of Chronic Rhinosinusitis with Nasal Polyposis.

The treatment involves receiving tezepelumab through injection. The medication will be given in doses up to 210 milligrams, with the total treatment period lasting up to 4 months. The total amount of medication received during the study will not exceed 840 milligrams.

The purpose of this study is to understand how tezepelumab affects the protective barrier of the airways in patients who have severe asthma, both with and without nasal polyps. The research will examine how the airways respond to various substances that can cause irritation. This will help researchers better understand how the medication works to protect the airways in these conditions.

The purpose of the study is to determine if patients who have been symptom-free for at least 12 months can safely stop their treatment without their symptoms returning. Participants in the study will have been receiving either Mepolizumab or Dupilumab regularly and will be monitored to see if they can maintain their symptom-free status after discontinuing the medication. The study will compare the outcomes of patients who stop treatment with those who continue, to see if there are any differences based on the medication used.

Throughout the study, participants will be closely observed to ensure their condition remains stable. The main goal is to find out what percentage of patients can stop their biologic treatment and still remain in complete remission, meaning they have no symptoms. The study will also look at whether there are any differences in outcomes based on which drug the patients were treated with. This research aims to provide valuable insights into the long-term management of Chronic Rhinosinusitis with Nasal Polyps.

The purpose of the study is to see how well Lebrikizumab works in reducing nasal congestion and the size of nasal polyps over a period of 24 weeks. Participants will be randomly assigned to receive either the treatment or the placebo, and neither the participants nor the researchers will know who is receiving which, to ensure unbiased results. The study will involve regular check-ups and assessments to monitor the condition of the participants and the effects of the treatment.

Throughout the study, participants will be asked to report their nasal congestion symptoms using a simple scale, and the size of their nasal polyps will be evaluated through a procedure called nasal endoscopy, which involves using a small camera to look inside the nose. The study aims to provide valuable information on whether Lebrikizumab can be an effective treatment option for people with Chronic Rhinosinusitis with Nasal Polyps.

The purpose of this study is to understand how Dupilumab affects ear symptoms and hearing function in patients with these conditions. Participants in the study will receive Dupilumab through subcutaneous injection, which means the medication is injected under the skin. The study will observe changes in symptoms and hearing over a period of time, specifically looking at how these change from the start of the treatment to 6 or 12 months later. Participants will be asked to complete questionnaires about their symptoms and undergo hearing tests to track any improvements or changes.

Throughout the study, researchers will monitor the participants’ progress by comparing their initial condition with their condition after receiving Dupilumab for several months. This will help determine the effectiveness of the treatment in managing symptoms related to chronic rhinosinusitis with nasal polyps and eosinophilic otitis media. The study aims to provide valuable insights into how Dupilumab can potentially improve the quality of life for individuals suffering from these conditions.

Participants in the study will receive either lunsekimig or a placebo over a period of time. The study will monitor changes in the size of nasal polyps using a special camera that looks inside the nose, as well as changes in symptoms reported by the participants themselves. These symptoms include nasal congestion, nasal discharge, and loss of smell. The study will also look at how the treatment affects the overall health of the sinuses using imaging techniques like CT scans, which create detailed pictures of the inside of the body.

Throughout the study, researchers will keep track of any side effects or adverse reactions to the treatment. They will also measure the levels of lunsekimig in the blood and check for any immune responses to the drug. The study is designed to provide important information about the safety and effectiveness of lunsekimig for treating CRSwNP, with the hope of offering a new option for people who struggle with this condition.

Participants in the study will receive either mepolizumab alone or a combination of surgery and mepolizumab. The surgery involved is called Functional Endoscopic Sinus Surgery (FESS), which is a procedure to remove nasal polyps and improve sinus drainage. The study will follow participants for 6 to 12 months to observe changes in their symptoms and overall condition.

The main focus of the study is to see how the treatment affects the severity of symptoms, including nasal polyps and sense of smell. The study will measure changes in a symptom score known as SNOT-22, which helps assess the impact of the condition on daily life. The goal is to determine the most effective way to manage CRSwNP and improve patients’ quality of life.

The purpose of the study is to evaluate how well benralizumab can reduce the size of nasal polyps and improve symptoms such as nasal blockage. Participants will receive either benralizumab or a placebo over a period of time, and their progress will be monitored through regular check-ups. The study will also look at other factors, such as changes in the sense of smell and the need for surgery or additional medication.

Throughout the study, participants will be asked to report their symptoms and any changes they experience. The study aims to provide valuable information on the effectiveness and safety of benralizumab for treating eosinophilic chronic rhinosinusitis with nasal polyps, potentially offering a new treatment option for those affected by this condition.

The purpose of the study is to evaluate how effective and safe Verekitug (UPB-101) is when used alongside standard nasal corticosteroid treatments. Participants in the study will receive either the new treatment or a placebo, which is a solution that looks like the treatment but contains no active medication. The study will last for about 24 weeks, during which participants will have regular check-ups to monitor their condition and any changes in their symptoms.

Throughout the study, participants will continue using their usual nasal spray treatment, and their progress will be closely observed by healthcare professionals. The study aims to provide valuable information on whether Verekitug (UPB-101) can help reduce the size of nasal polyps and improve symptoms for those living with this chronic condition.

The purpose of the study is to understand how Dupilumab impacts the nasal barrier function, which is the ability of the nasal lining to protect against harmful substances. Participants will receive Dupilumab treatment over a period of six months. The study will involve regular visits to monitor changes in the nasal barrier and other related factors. Some participants will receive a placebo for comparison.

Throughout the study, researchers will collect samples and data to assess changes in the nasal lining and other biological markers. This will help determine the effectiveness of Dupilumab in improving the condition of patients with CRSwNP. The study aims to provide valuable insights into the treatment of chronic rhinosinusitis and the role of Dupilumab in managing this condition.

The purpose of the study is to see if mepolizumab can improve the quality of life for people with CRS, as measured by a questionnaire called the sinonasal outcome test (SNOT-22). Participants in the study will be divided into three groups. Some will receive mepolizumab, while others may undergo a procedure called nasal polypectomy, which is a minor surgery to remove polyps from the nose. There is also a possibility of receiving a placebo, which is a substance with no active medication. The study will monitor participants over a period of time to assess changes in their symptoms and overall well-being.

Throughout the study, various aspects will be evaluated, such as nasal symptoms, the need for additional treatments like corticosteroids, and any potential side effects of the treatment. The safety of mepolizumab will be closely monitored by collecting information on any adverse events during the study visits. The trial aims to provide valuable insights into how effective mepolizumab is in managing chronic rhinosinusitis with nasal polyps and improving patients’ lives.

The purpose of the study is to determine how effective each medication is in treating the symptoms of chronic rhinosinusitis with nasal polyposis. Participants in the study will receive either dupilumab or mepolizumab and will be monitored over a period of time to assess changes in their symptoms. The study will look at both objective measures, such as the size of the nasal polyps, and subjective measures, like the patient’s sense of smell and overall quality of life.

Throughout the study, participants will be asked to attend regular check-ups to track their progress. The study will last for a specified period, during which the effectiveness of the treatments will be evaluated. The goal is to see if one medication is superior to the other or if they are equally effective in managing the symptoms of chronic rhinosinusitis with nasal polyposis.

The purpose of the study is to explore how Dupilumab can help restore the barrier function in the airways of patients with CRSwNP. Participants will receive either Dupilumab or a placebo in addition to their standard care for CRSwNP and/or asthma. The study will last for 24 weeks, during which time the effects of the treatment on nasal tissue and other health markers will be monitored. This includes looking at changes in certain proteins and genes in the nasal tissue, as well as other health indicators in the blood.

Throughout the study, participants will have regular check-ups to assess their condition and the impact of the treatment. The study aims to provide insights into how Dupilumab can improve the symptoms and quality of life for people with CRSwNP. Participants will be monitored for changes in their symptoms and overall health, with the goal of understanding the potential benefits of adding Dupilumab to their treatment plan.

The purpose of this study is to evaluate how effective secukinumab is in reducing symptoms for patients with a specific type of CRSwNP, known as non-type 2 CRSwNP. Participants in the study will receive secukinumab as an injection under the skin, using a pre-filled syringe. The study will last for a period of 16 weeks, during which the effects of the treatment on symptoms will be monitored. Participants will be assessed on changes in their symptoms and any improvements in their condition.

Throughout the study, researchers will also look at changes in certain markers in the body that are associated with inflammation. This will help to understand how secukinumab affects the underlying inflammation in CRSwNP. The study aims to provide valuable information on whether secukinumab can be a beneficial treatment option for people with this challenging condition.